Hematoma Risk: Clopidogrel vs Aspirin
When used as monotherapy, clopidogrel and aspirin have similar rates of hematoma formation, but clopidogrel causes slightly more epistaxis and hematoma events compared to aspirin's higher gastrointestinal bleeding risk.
Direct Head-to-Head Comparison
The CAPRIE trial provides the most definitive monotherapy comparison data. In this large trial, epistaxis and hematoma were reported more frequently in the clopidogrel group, while aspirin caused more gastrointestinal hemorrhage (2.7% vs 2.0%) 1. However, bleeding requiring hospitalization was actually lower with clopidogrel (0.7%) compared to aspirin (1.1%), and intracranial hemorrhage rates were nearly identical (0.4% vs 0.5%) 1.
Key Clinical Context
The distinction becomes critical in specific surgical settings:
Carotid Endarterectomy Data
In patients undergoing carotid surgery, clopidogrel monotherapy showed a relative risk of 1.9 for wound hematoma compared to aspirin alone 2. More importantly, severe space-occupying hematomas requiring surgical re-exploration occurred in 4.3% of clopidogrel patients versus only 1.2% of aspirin patients (relative risk 3.7) 2.
Cardiac Device Implantation
For cardiac rhythm device procedures, aspirin or clopidogrel monotherapy had similarly low hematoma rates (3.9% and 1.2% respectively), both comparable to no antithrombotic therapy 3.
Critical Pitfall: Dual Antiplatelet Therapy
The combination of aspirin plus clopidogrel dramatically increases hematoma risk compared to either agent alone. In the CURE trial, dual therapy caused major bleeding in 3.7% versus 2.7% with aspirin alone 4, 1. For surgical procedures:
- Dual therapy increased wound hematoma risk 2.4-fold compared to aspirin monotherapy 2
- Pocket hematoma rates jumped to 16.2% with dual therapy versus 2.1% with no antiplatelet therapy 3
Clinical Bottom Line
For monotherapy:
- Aspirin causes more GI bleeding but less surgical site hematoma
- Clopidogrel causes more epistaxis and surgical wound hematomas but less GI bleeding
- Both have equivalent intracranial hemorrhage risk
In surgical contexts where wound hematoma is the primary concern (carotid surgery, device implantation), aspirin monotherapy carries lower risk than clopidogrel 2. However, for non-surgical bleeding overall, the drugs are roughly equivalent, with clopidogrel potentially safer given lower hospitalization rates for bleeding 1.
The most recent 2025-2026 data confirms these patterns remain consistent, with clopidogrel showing stronger CNS hematoma signals in pharmacovigilance databases but no difference in major bleeding versus aspirin in clinical trials 5, 6.